Empagliflozin-Associated Adverse Effects

Common Adverse Effects

The American College of Cardiology notes that the most common adverse effects of empagliflozin include genital mycotic infections, urinary tract infections, volume depletion effects, and risk of euglycemic ketoacidosis 1
Clinical trials, including EMPA-RESPONSE-AHF, did not report diarrhea as a significant adverse event, as reported by the Journal of the American College of Cardiology 2, 3

The American Diabetes Association, as reported in Diabetes Care, notes that sotagliflozin, a dual SGLT1/SGLT2 inhibitor, has been associated with diarrhea in clinical trials, likely due to its SGLT1 inhibition in the intestines 4, 5
In the SOLOIST-WHF trial, diarrhea was specifically noted as a common adverse effect with sotagliflozin but not with empagliflozin, as reported by the Journal of the American College of Cardiology and Diabetes Care 2, 5

For patients concerned about gastrointestinal side effects, empagliflozin may be a better choice compared to sotagliflozin or other medications known to cause diarrhea, as reported in Diabetes Care 4, 5
In patients with type 2 diabetes who have heart failure, empagliflozin has shown significant cardiovascular benefits without notable gastrointestinal adverse effects, as reported in Diabetes Care 5